223 related articles for article (PubMed ID: 28939770)
21. Myristoylation and membrane binding regulate c-Src stability and kinase activity.
Patwardhan P; Resh MD
Mol Cell Biol; 2010 Sep; 30(17):4094-107. PubMed ID: 20584982
[TBL] [Abstract][Full Text] [Related]
22. Targeting the yin and the yang: combined inhibition of the tyrosine kinase c-Src and the tyrosine phosphatase SHP-2 disrupts pancreatic cancer signaling and biology in vitro and tumor formation in vivo.
Gomes EG; Connelly SF; Summy JM
Pancreas; 2013 Jul; 42(5):795-806. PubMed ID: 23271399
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model.
Trevino JG; Summy JM; Lesslie DP; Parikh NU; Hong DS; Lee FY; Donato NJ; Abbruzzese JL; Baker CH; Gallick GE
Am J Pathol; 2006 Mar; 168(3):962-72. PubMed ID: 16507911
[TBL] [Abstract][Full Text] [Related]
24. Pharmacologically targeting the myristoylation of the scaffold protein FRS2α inhibits FGF/FGFR-mediated oncogenic signaling and tumor progression.
Li Q; Alsaidan OA; Ma Y; Kim S; Liu J; Albers T; Liu K; Beharry Z; Zhao S; Wang F; Lebedyeva I; Cai H
J Biol Chem; 2018 Apr; 293(17):6434-6448. PubMed ID: 29540482
[TBL] [Abstract][Full Text] [Related]
25. Downregulation of c-SRC kinase CSK promotes castration resistant prostate cancer and pinpoints a novel disease subclass.
Yang CC; Fazli L; Loguercio S; Zharkikh I; Aza-Blanc P; Gleave ME; Wolf DA
Oncotarget; 2015 Sep; 6(26):22060-71. PubMed ID: 26091350
[TBL] [Abstract][Full Text] [Related]
26. Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.
Formisano L; D'Amato V; Servetto A; Brillante S; Raimondo L; Di Mauro C; Marciano R; Orsini RC; Cosconati S; Randazzo A; Parsons SJ; Montuori N; Veneziani BM; De Placido S; Rosa R; Bianco R
Oncotarget; 2015 Sep; 6(28):26090-103. PubMed ID: 26325669
[TBL] [Abstract][Full Text] [Related]
27. Targeting N-myristoylation for therapy of B-cell lymphomas.
Beauchamp E; Yap MC; Iyer A; Perinpanayagam MA; Gamma JM; Vincent KM; Lakshmanan M; Raju A; Tergaonkar V; Tan SY; Lim ST; Dong WF; Postovit LM; Read KD; Gray DW; Wyatt PG; Mackey JR; Berthiaume LG
Nat Commun; 2020 Oct; 11(1):5348. PubMed ID: 33093447
[TBL] [Abstract][Full Text] [Related]
28. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells.
Nam S; Kim D; Cheng JQ; Zhang S; Lee JH; Buettner R; Mirosevich J; Lee FY; Jove R
Cancer Res; 2005 Oct; 65(20):9185-9. PubMed ID: 16230377
[TBL] [Abstract][Full Text] [Related]
29. Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model.
Yang JC; Bai L; Yap S; Gao AC; Kung HJ; Evans CP
Mol Cancer Ther; 2010 Jun; 9(6):1629-37. PubMed ID: 20484016
[TBL] [Abstract][Full Text] [Related]
30. Platycodin D induces tumor growth arrest by activating FOXO3a expression in prostate cancer in vitro and in vivo.
Zhou R; Lu Z; Liu K; Guo J; Liu J; Zhou Y; Yang J; Mi M; Xu H
Curr Cancer Drug Targets; 2015; 14(9):860-71. PubMed ID: 25431082
[TBL] [Abstract][Full Text] [Related]
31. Arctigenin inhibits prostate tumor growth in high-fat diet fed mice through dual actions on adipose tissue and tumor.
Hao Q; Diaz T; Verduzco ADR; Magyar CE; Zhong J; Elshimali Y; Rettig MB; Henning SM; Vadgama JV; Wang P
Sci Rep; 2020 Jan; 10(1):1403. PubMed ID: 31996731
[TBL] [Abstract][Full Text] [Related]
32. Paracrine Fibroblast Growth Factor Initiates Oncogenic Synergy with Epithelial FGFR/Src Transformation in Prostate Tumor Progression.
Li Q; Ingram L; Kim S; Beharry Z; Cooper JA; Cai H
Neoplasia; 2018 Mar; 20(3):233-243. PubMed ID: 29444487
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of oncogenic Src induces FABP4-mediated lipolysis via PPARγ activation exerting cancer growth suppression.
Hua TNM; Kim MK; Vo VTA; Choi JW; Choi JH; Kim HW; Cha SK; Park KS; Jeong Y
EBioMedicine; 2019 Mar; 41():134-145. PubMed ID: 30755372
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
Kim A; Seong KM; Kang HJ; Park S; Lee SS
Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of Src impairs the growth of met-addicted gastric tumors.
Bertotti A; Bracco C; Girolami F; Torti D; Gastaldi S; Galimi F; Medico E; Elvin P; Comoglio PM; Trusolino L
Clin Cancer Res; 2010 Aug; 16(15):3933-43. PubMed ID: 20628031
[TBL] [Abstract][Full Text] [Related]
36. Linking γ-aminobutyric acid A receptor to epidermal growth factor receptor pathways activation in human prostate cancer.
Wu W; Yang Q; Fung KM; Humphreys MR; Brame LS; Cao A; Fang YT; Shih PT; Kropp BP; Lin HK
Mol Cell Endocrinol; 2014 Mar; 383(1-2):69-79. PubMed ID: 24296312
[TBL] [Abstract][Full Text] [Related]
37. Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer.
Edwards J
Expert Opin Investig Drugs; 2010 May; 19(5):605-14. PubMed ID: 20367532
[TBL] [Abstract][Full Text] [Related]
38. High-fat diet in a mouse insulin-resistant model induces widespread rewiring of the phosphotyrosine signaling network.
Dittmann A; Kennedy NJ; Soltero NL; Morshed N; Mana MD; Yilmaz ÖH; Davis RJ; White FM
Mol Syst Biol; 2019 Aug; 15(8):e8849. PubMed ID: 31464373
[TBL] [Abstract][Full Text] [Related]
39. Blocking AMPK β1 myristoylation enhances AMPK activity and protects mice from high-fat diet-induced obesity and hepatic steatosis.
Neopane K; Kozlov N; Negoita F; Murray-Segal L; Brink R; Hoque A; Ovens AJ; Tjin G; McAloon LM; Yu D; Ling NXY; Sanders MJ; Oakhill JS; Scott JW; Steinberg GR; Loh K; Kemp BE; Sakamoto K; Galic S
Cell Rep; 2022 Dec; 41(12):111862. PubMed ID: 36543129
[TBL] [Abstract][Full Text] [Related]
40. Targeting Src-mediated Tyr216 phosphorylation and activation of GSK-3 in prostate cancer cells inhibit prostate cancer progression in vitro and in vivo.
Goc A; Al-Husein B; Katsanevas K; Steinbach A; Lou U; Sabbineni H; DeRemer DL; Somanath PR
Oncotarget; 2014 Feb; 5(3):775-87. PubMed ID: 24519956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
